Mammary Analogue Secretory Carcinoma of Salivary Gland … Conf PDFs/23 B - Sat Case...sweat duct...
48
A Cutaneous Facial Mass Identified as the New Entity ‘Mammary Analogue Secretory Carcinoma’ of Probable Salivary Gland Origin Scott W. Binder, MD Professor and Senior Vice Chair Chief, Dermatopathology Geffen/UCLA Healthcare
Transcript of Mammary Analogue Secretory Carcinoma of Salivary Gland … Conf PDFs/23 B - Sat Case...sweat duct...
A Cutaneous Facial Mass Identified as the New Entity ‘Mammary Analogue Secretory Carcinoma’ of Probable Salivary Gland Origin
Scott W. Binder, MD Professor and Senior Vice Chair
Chief, Dermatopathology
Geffen/UCLA Healthcare
Case Presentation
A 50 year-old man presents with a 7 mm erythematous papule on the right face
• Developed over a few months
• Asymptomatic
• No history of prior neoplasms including salivary gland tumors
• Lesion located just lateral to nose
Presenter
Presentation Notes
We have a 50-year-old man who presented with an asymptomatic, small erythematous papule on the R face, which had been present for 3 months.
Clinical Impression
“Rule out bug bite”
Presenter
Presentation Notes
The lesion was biopsied to “rule out a bug bite”
Histopathology
4
Histopathology
5
Histopathology
6
Histopathology
7
Histopathology
8
Histopathology
9
Differential Diagnoses
• Acinic cell carcinoma
• Apocrine or eccrine sweat duct tumor
• Mammary analogue secretory carcinoma
• Benign oncocytic neoplasms
• Mucoepidermoid carcinoma
• Metastasis from a visceral primary
Presenter
Presentation Notes
A tumor with this morphology has a limited differential. Until recently, the identification of a microcystic architecture within a primary salivary gland neoplasm would have been strong evidence in support of a diagnosis of acinic cell carcinoma. Serous acinar granules within the cytoplasm of tumor cells would carefully searched for, and if not apparent on routine H&E stains, a PAS plus diastase stain would be applied to aid in the search. Depending on the findings elsewhere, and assuming no acinar granules identified, the tumor in the past might have been termed low-grade adenocarcinoma (favor acinic cell carcinoma) or, if other features supported, simply acinic cell carcinoma. Now, with the description of the entity known as mammary analogue secretory carcinoma (MASC), further study is necessary to identify the presence of some of the characteristics of this lesions.
Outside Special Stains
S-100 EMA CK 7
CK 20 p63 Mucicarmine
Presenter
Presentation Notes
Immunostains performed at the referring institution and interpreted by us reveal patchy positive staining of tumor cells with antibodies to S-100 protein. There is strong positive staining of lesional tissues with antibodies to EMA and cytokeratin 7 and negative staining with cytokeratin 20. P63 was negative. Mucicarmine stain appears focally positive.
Additional Immunohistochemistry
Mammaglobin CEA CK 5/6 Thyroglobin
TTF-1 PSA Ki67
Presenter
Presentation Notes
The Immunohistochemical staining performed at UCLA and interpreted by us reveals strong positive staining of tumor cells with antibodies to mammaglobin. There is focal positive staining of tumor cells with antibodies to CEA. There is negative staining of tumor cells with antibodies to cytokeratin 5/6, thyroglobulin, TTF-1 (with high background), PSA. Ki-67 reveals a moderate nuclear proliferation rate.
Diagnosis
• Mammary Analogue Secretory Carcinoma (MASC) •? Primary salivary gland origin v. primary cutaneous tumor
• Rule out metastasis
Presenter
Presentation Notes
The constellation of histologic and immunologic features favors a low-grade carcinoma, suggestive of mammary analogue secretory carcinoma of salivary gland origin. The lesion appears quite cellular and demonstrates and infiltrative growth pattern, both atypical features. We want to emphasize some features of the immunologic staining pattern. Negative staining of this tumor with antibodies to p63 and cytokeratin 5/6 argue against a primary cutaneous sweat duct tumor and suggest the possibility of a metastasis from a visceral primary. The strong positive staining with mammaglobin may reflect a breast or salivary gland origin. So-called mammary analogue secretory carcinoma of the salivary gland may show positive immunostaining with S100, CK7, and mammaglobin, as seen in this tumor. Strong positive staining of tumor cells with antibodies to EMA is consistent with low grade carcinoma of MASC-type.
Background
• MASC first described in 2010 by Skalova et al.
• Morphologic overlap between acinic cell carcinoma and secretory carcinoma of the breast
• Tumors affect all ages (range 14-77), slightly male-predominant
Presenter
Presentation Notes
MASC was initially described in a series of 16 cases by Skalova et al in 2010. The authors had identified in their consultation practices a tumor that showed morphologic overlap between acinic cell carcinoma and secretory carcinoma of the breast. Since the initial description, there have been several additional reports describing small series of cases designated as MASC. The tumors affect patients over a wide age range, from 14 to 77, with an average age of 44 years. Males have been affected more frequently (21M:F14)
MASC
• Presents as slowly growing mass, often near parotid gland
• No evidence of primary cutaneous origin, as of yet
• Most treated with non-radical excision +/-radiotherapy
• Cases of lymph node metastases, local recurrences, low mortality Chiosea et al, Histopathology 2012
Presenter
Presentation Notes
Most presented with a slow growing mass. In 23 cases the parotid was the site of involvement, while oral sites made up the bulk of the remainder (lip, palate, and buccal mucosa). In 2 cases, the submandibular gland was involved. The tumors varied in size from 0.7-5.5cm. Most patients were treated with non-radical excision with or without radiotherapy. There is limited follow-up information, but 2 patients in the original series died of disease after 2 and 6 years, while 4 patients had local recurrences. Lymph node metastases have been identified in 3 patients – two at the time of diagnosis, and in another 86 months after initial treatment.
Histology of MASC
• Unencapsulated, lobulated
• Intercalated duct cells in tubular, microcystic, papillary patterns
• Lumina with ample “bubbly” secretions (mucicarmine +)
• Absence of serous acinar granules
Presenter
Presentation Notes
Microscopic descriptions of MASC have been generally uniform, with unencapsulated lobular tumor made of cuboidal cells arranged in ductal, papillary, microcystic patterns. Microcystic architecture is most common, with abundant secretions in the lumina that stain with mucicarmine and PASD. Unlike in AiCC, serous acinar granules tend to be absent, although this is not absolute. Staining is positive for S100, CK7, EMA, mammoglobin, GCDFP. Basal cell/ myoepithelial markers are negative (p63, calponin, CK5/6
Immunohistochemistry of MASC Staining • Usually positive
•S100
•CK7
•Vimentin • Often positive
• EMA
• GCDFP
• Mammaglobin
• Negative
• CK5/6, CK20
• P63, TTF-1, PSA, Thyroglobulin
17
Immunohistochemistry of most apocrine tumors
• Cytokeratin 5/6+, p63+ • S100+/-, cytokeratin 7+ • Mammaglobin +/-, EMA+ (patchy, highlights ducts) • CEA+, GCDFP 15+/-
18
Key Differential Diagnoses of MASC
Diagnosis Key Cytomorphologic Features
Ancillary Testing Features
Benign oncocytic neoplasms (oncocytoma, oncocytic cystadenoma, Warthin tumor)
Lack vacuolated cytoplasm, more cohesive
S-100 negative, anti-mitochondrial antibody positive
Acinic cell carcinoma Usually lacks mucin PAS-D+ cytoplasmic granules, DOG-1 strongly positive, mammaglobin negative
Mucoepidermoid carcinoma
Epidermoid differentiation p63 positive, S100 negative, MAML2 translocation
Metastatic carcinoma High grade nuclei, many show necrosis
Staining variable
19
Fusion Gene
• Almost all MASC had fusion gene ETV6-NTRK3
Normal Cells No ETV6 Split Signals Abnormal ETV6 split signals
Presenter
Presentation Notes
Lastly, all cases of MASC, except one have exhibited a t(12;15)(p13;q25) rearrangement leading to ETV6-NTRK3 fusion. We performed FISH studies in our case, which showed the 12p13 region involved as exhibited by the spilt signals of the ETV6 dual color breakpart probe. A normal cell would show both the red and green signals in close proximity while any rearrangement will show spilt or other signal pattern consistent with 12p13 abnormality. What you see is a fair amount of genomic heterogeneity suggestive of unbalanced rearrangement. The verdict is that there is indeed a ETV6 translocation in over 90% of the cells analyzed. This test is an extremely useful test to distinguish MASC from other tumors. And it was confirmed in our patient.
Clinical Course
• Patient had neoplasm completely excised by the ENT service
• Work-up for primary underlying neoplasm is on-going and imaging studies are negative for primary salivary gland tumor
Summary
• MASC is likely an under-recognized diagnosis and can present a diagnostic pitfall, easily being confused with a primary adnexal tumor given that it is a newly-described entity and too bland to be immediately interpreted as a metastasis or recurrence. The origin of this particular tumor is still uncertain, as no salivary gland primary has been detected in this patient.
• Immunohistochemical stains for S100, CK7, p63, cytokeratin 5/6, mammaglobin, and identification of the ETV6-NTRK3 fusion gene would be required to completely evaluate tumors of this type
• ? Primary cutaneous/subcutis MASC v. unusual primary apocrine sweat duct tumor (solid and cystic hidradenoma)
Presenter
Presentation Notes
First, one sees bland-appearing tumors which have resembled sweat duct tumors in the past which eventually were discovered to be metastases from occult visceral sites such as the salivary gland, breast, or lung. Therefore, keep MASC in mind. Second, cytologic features in combination with immunostaining and cytogenetic analysis can distinguish this entity from others in the differential diagnoses, such as acinic cell carcinoma.
Cutaneous Metastases v. Adnexal Primary Carcinoma: A Practical Approach
23
Cutaneous Metastases
• Clinical Considerations •Mean age at presentation is 62 •Most common primary tumors
• Lung 30% • Melanoma 18% • G.I. Tract 14% • Breast 5% • Lymphoma 5%
•In approximately 10% of cases, the primary is unknown • Histologic Types
•Adenocarcinoma 40% •Melanoma 15% •Squamous carcinoma 15% •Other 30%
24
Cutaneous Metastases v. Primary Adnexal Carcinoma
• Histopathologic Characteristics of Metastases •Tumor growth often concentrated in the deep dermis - “bottom heavy” appearance
•Sparing of epidermis common •Ulceration and pagetoid spread rarely noted (colonic and melanoma)
•Tumor necrosis sometimes present
•Lymph/vascular invasion sometimes observed •High grade tumor cells with numerous mitoses
25
Cutaneous Metastases v. Primary Adnexal Carcinoma
• Immunohistochemical Considerations •Battery may include
•Cytokeratin 7 •Cytokeratin 20 •S-100 •MART-1/Melan-A/MITF or SOX-10 •PSA •TTF-1 •ER/PR/Her-2-neu •CDX-2 •Cytokeratin 5/6, p63*
26
Cutaneous Metastases v. Primary Adnexal Carcinoma
• Recent studies have shown that CK5/6 and p63 may help distinguish primary adnexal neoplasms (CK5/6+/p63+) from most metastatic carcinomas (CK5/6-/p63-)
• P63 especially helpful • D2-40 not been especially helpful in my lab
27
46 yo F with history of breast cancer x7 years
28
Histopathology
29
Histopathology
30
Histopathology
31
IHC Results
32
CK7
IHC Results
33
ER
IHC Results
34
HER2/neu
IHC Results
35
CK5/6
IHC Results
36
P63
68 yo M w paranasal mass present x 1 yr – rapid recent growth
37
Histopathology
38
Histopathology
39
Histopathology
40
IHC Results
41
CK5/6
IHC Results
42
p63
Cutaneous Metastases v. Primary Adnexal Carcinoma
• Impossible to reliably distinguish primary or metastatic eccrine/apocrine tumors from cutaneous metastases of breast carcinomas, especially apocrine or mucinous types
• Immunohistochemical Staining of Breast v. Metastases •ER (estrogen receptor) •PR (progesterone receptor) •GCDFP-15 (gross cystic disease fluid protein) •CEA •Her-2-neu
• None of these may reliably separate primary sweat duct tumors from breast metastases
43
Cutaneous Metastases v. Primary Adnexal Carcinoma
• Aberrant staining of metastases •Technical
•Antibody •Technique
•Therapeutic effect – chemo and/or radiation/immune modulators •Tumor metastases may have different immuno phenotypes than the primary •Tumors don’t always read the books •Another tumor/primary is responsible for the aberrant staining
44
Cutaneous Metastases v. Primary Adnexal Carcinoma
• Take Home •H&E considerations and clinical information most important for diagnostic purposes •Immunohistochemistry stains are useful ancillary studies, especially cytokeratin 5/6 and p63 but be careful as these may lead you astray •Be sure to eliminate the possibility of a basal cell carcinoma demonstrating unusual growth patterns •Always think of the possibility of a primary adnexal CA in the appropriate clinical and histologic context •Occasional inability to differentiate a primary adnexal CA from a visceral metastasis
45
References
• Saliva A, Vanecek T, Sima R, Laco J, Weinreb I, Perez-Ordonez B, Starek I, Geierova M, Simpson RH, Passador-Santos F, Ryska A, Leivo I, Kinkor Z, Michal M. Mammary analogue secretory carcinoma of salivary glands, containing the ETV6-NTRK3 fusion gene: a hitherto undescribed salivary gland tumor entity. Am J Surg Pathol. 2010 May;34(5):599-608.
•Griffith C, Seethala R, Chiosea SI. Mammary analogue secretory carcinoma: a new twist to the diagnostic dilemma of zymogen granule poor acinic cell carcinoma. Virchows Arch. 2011 Jul;459(1):117-8.
• Fehr A, Löning T, Stenman G. Mammary analogue secretory carcinoma of the salivary glands with ETV6-NTRK3 gene fusion. Am J Surg Pathol. 2011 Oct;35(10):1600-2.
•Rastatter JC, Jatana KR, Jennings LJ, Melin-Aldana H. Mammary analogue secretory carcinoma of the parotid gland in a pediatric patient. Otolaryngol Head Neck Surg. 2012 Mar;146(3):514-5.
•Connor A, Perez-Ordoñez B, Shago M, Skálová A, Weinreb I. Mammary analog secretory carcinoma of salivary gland origin with the ETV6 gene rearrangement by FISH: expanded morphologic and immunohistochemical spectrum of a recently described entity. Am J Surg Pathol. 2012 Jan;36(1):27-34.
•Chiosea SI, Griffith C, Assaad A, Seethala RR. Clinicopathological characterization of mammary analogue secretory carcinoma of salivary glands. Histopathology. 2012 Sep;61(3):387-94.
•Griffith CC, Stelow EB, Saqi A, Khalbuss WE, Schneider F, Chiosea SI, Seethala RR. The cytological features of mammary analogue secretory carcinoma: a series of 6 molecularly confirmed cases. Cancer Cytopathol. 2013 May;121(5):234-41.
•Bishop JA. Unmasking MASC: bringing to light the unique morphologic, immunohistochemical and genetic features of the newly recognized mammary analogue secretory carcinoma of salivary glands. Head Neck Pathol. 2013 Mar;7(1):35-9.
References
• Jung MJ, Song JS, Kim SY, Nam SY, Roh JL, Choi SH, Kim SB, Cho KJ. Finding and characterizing mammary analogue secretory carcinoma of the salivary gland. Korean J Pathol. 2013 Feb;47(1):36-43.
•Hwang MJ, Wu PR, Chen CM, Chen CY, Chen CJ. A rare malignancy of the parotid gland in a 13-year-old Taiwanese boy: case report of a mammary analogue secretory carcinoma of the salivary gland with molecular study. Med Mol Morphol. 2013 Aug 18.
•Knezevich SR, Garnett MJ, Pysher TJ, et al. ETV6-NTRK3 gene fusions and trisomy 11 establish a histogenetic link between mesoblastic nephroma and congenital fibrosarcoma. Cancer Res. 1998;15:5046–5048.
•Makretsov N, He M, Hayes M, et al. A fluorescence in situ hybridization study of ETV6-NTRK3 fusion gene in secretory breast carcinoma. Genes Chromosomes Cancer. 2004;40:152–157.
•Rastatter JC, Jatana KR, Jennings LJ, Melin-Aldana H. Mammary analogue secretory carcinoma of the parotid gland in a pediatric patient. Otolaryngol Head Neck Surg. 2012 Mar;146(3):514-5.
•Connor A, Perez-Ordoñez B, Shago M, Skálová A, Weinreb I. Mammary analog secretory carcinoma of salivary gland origin with the ETV6 gene rearrangement by FISH: expanded morphologic and immunohistochemical spectrum of a recently described entity. Am J Surg Pathol. 2012 Jan;36(1):27-34.
•Chiosea SI, Griffith C, Assaad A, Seethala RR. Clinicopathological characterization of mammary analogue secretory carcinoma of salivary glands. Histopathology. 2012 Sep;61(3):387-94.
References
•Griffith CC, Stelow EB, Saqi A, Khalbuss WE, Schneider F, Chiosea SI, Seethala RR. The cytological features of mammary analogue secretory carcinoma: a series of 6 molecularly confirmed cases. Cancer Cytopathol. 2013 May;121(5):234-41.
•Bishop JA. Unmasking MASC: bringing to light the unique morphologic, immunohistochemical and genetic features of the newly recognized mammary analogue secretory carcinoma of salivary glands. Head Neck Pathol. 2013 Mar;7(1):35-9.
•Jung MJ, Song JS, Kim SY, Nam SY, Roh JL, Choi SH, Kim SB, Cho KJ. Finding and characterizing mammary analogue secretory carcinoma of the salivary gland. Korean J Pathol. 2013 Feb;47(1):36-43.
•Hwang MJ, Wu PR, Chen CM, Chen CY, Chen CJ. A rare malignancy of the parotid gland in a 13-year-old Taiwanese boy: case report of a mammary analogue secretory carcinoma of the salivary gland with molecular study. Med Mol Morphol. 2013 Aug 18.
•Knezevich SR, Garnett MJ, Pysher TJ, et al. ETV6-NTRK3 gene fusions and trisomy 11 establish a histogenetic link between mesoblastic nephroma and congenital fibrosarcoma. Cancer Res. 1998;15:5046–5048.
•Makretsov N, He M, Hayes M, et al. A fluorescence in situ hybridization study of ETV6-NTRK3 fusion gene in secretory breast carcinoma. Genes Chromosomes Cancer. 2004;40:152–157.
